Scripps Whittier Diabetes Institute
Type 2 Mobile App Study

The clinical research team at Scripps Whittier Diabetes Institute is conducting a new study for people with type 2 diabetes on long acting insulin. This study will evaluate whether the use of a smartphone app that helps with insulin management can improve blood glucose control.

TO BE ELIGIBLE*, YOU MUST:

  • Be 18 years of age or older
  • Be diagnosed with type 2 diabetes mellitus
  • Be currently on long acting insulin (i.e. Lantus, Tresiba, Levemir, Toujeo, Basaglar) or about to start a long acting insulin
  • Not be on mealtime insulin or steroids
  • Have HbA1c between 7.5-12.5%
  • Have a smart mobile device (iPhone, Android phone, etc.) with data or Wi-Fi capability
  • Actively use a blood glucose meter
  • Be able to speak, read, and write in English

PARTICIPATION INVOLVES:

  • Three or four in-person study visits (at a Scripps Clinic) over a 16-week period; participants will be compensated for each completed visit ($300 total for all visits)
  • Tresiba insulin, lancets, strips supply for 16 weeks period (at no cost to the patient)
  • Lab tests (at no cost to the patient) for HbA1c
  • Check your fasting blood sugar daily
  • Bringing in your blood glucose meter to upload at the study visits
  • Complete questionnaires on feelings and attitudes towards diabetes at two study visits

This is a voluntary study and you have the option of withdrawing at any time. Your information will be kept confidential.

*Additional inclusion/exclusion criteria may apply.

To find out more information or if you have any questions, please feel free to contact:

Alessandra Kitishian, RD, CDE, MBA, MPM, Clinical Research Project Manager

858-678-7982

Kitishian.Alessandra@scrippshealth.org

Click below for a pdf of the flyer.

GL3 Study Recruitment Flyer_05 14

2 Comments
  1. I am interested in your study.

Leave a Reply